Cure Rate After Chemotherapy in Stage III Ovarian Cancer
Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured.
Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured.
Many patients with advanced ovarian cancer may be eligible for first-line maintenance with a PARP inhibitor, research suggests.
A randomized study sought to determine the effect of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy on HRQOL for patients with advanced ovarian cancer.
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
Despite the lack of improvement in the overall cohort, olaparib monotherapy and olaparib-cediranib did exhibit activity in a subset of patients with a germline BRCA mutation.
An interview study was conducted to determine preferences regarding information related to genetic counseling and testing among patients with ovarian cancer.
A cross-sectional study sought to determine how caregiving responsibilities affect mental health of partner-caregivers.
Avelumab did not improve progression-free survival when given concurrently with chemotherapy or as maintenance.
Most adverse events in the olaparib arm were manageable with supportive treatment or dose modifications.